X

Get our occasional Market Report emails

sent straight to your inbox

There’s no charge for this.

Getting latest data loading
X

Request a Call to Trade

In addition to the daily Research emails, I would also like to receive the Accendo Markets Weekly Newsletter and occasional Market Report emails highlighting various trading opportunities.
When you enter your telephone number, we may call or message you occasionally with trading opportunities. You can opt out at any time
Home / Support and Resistance / Mediclinic International (MDC.L) 20-04-20

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

Mediclinic International (MDC.L) 20-04-20

Will Mediclinic International (MDC.L) shares break below the 250p support, or return to highs of 415p (+65%)?

  • Currently close to the 250p support at 251.2p (at time of writing).
  • This has been identified for ostensibly strong support level. Traders should consider whether they think it will hold up again.
  • Will the price bounce again to recent highs at 415p? (+65%).
  • Technical traders should consider potential news and developments. Check our website and the press for updates in future.
  • Shares -39% from 12-month highs; +2% from 12 month lows.

Latest News

17 Apr:  Mediclinic International, the healthcare company,  announced it had paused dividends and had reached an agreement on debt covenant waivers, due to concerns over the Covid-19 pandemic.

14 Apr:  HSBC reiterates its reduce rating on Mediclinic International Plc (MDC) and reduced the target price to 270p (from 310p).

27 Mar:  Mediclinic announced that it had appointed Inga Beale as chairman.  She is due to replace Edwin Hertzog following his retirement.

07 Feb:  Mediclinic announced it had obtained competition clearance on its proposed acquisition of South Africa’s Matlosana Medical Health Services.

21 Jan:  Jefferies International reiterates its buy rating on Mediclinic International Plc (MDC) and increased the target price to 482p (from 457p).

18 Dec:  Barclays Capital reiterates its equal weight rating on Mediclinic International Plc (MDC) and increased the target price to 400p (from 360p).

Source: Bloomberg, Reuters, Alpha Terminal, FT, DJ Newswires

Click to enlarge

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.